Role of Stat3 in regulating p53 expression and function

Guilian Niu, Kenneth L. Wright, Yihong Ma, Gabriela M. Wright, Mei Huang, Rosalyn Irby, Jon Briggs, James Karras, W. Douglas Cress, Andrew Mark Pardoll, Richard Jove, Jiangdong Chen, Hua Yu

Research output: Contribution to journalArticle

Abstract

Loss of p53 function by mutation is common in cancer. However, most natural p53 mutations occur at a late stage in tumor development, and many clinically detectable cancers have reduced p53 expression but no p53 mutations. It remains to be fully determined what mechanisms disable p53 during malignant initiation and in cancers without mutations that directly affect p53. We show here that oncogenic signaling pathways inhibit the p53 gene transcription rate through a mechanism involving Stat3, which binds to the p53 promoter in vitro and in vivo. Site-specific mutation of a Stat3 DNA-binding site in the p53 promoter partially abrogates Stat3-induced inhibition. Stat3 activity also influences p53 response genes and affects UV-induced cell growth arrest in normal cells. Furthermore, blocking Stat3 in cancer cells up-regulates expression of p53, leading to p53-mediated tumor cell apoptosis. As a point of convergence for many oncogenic signaling pathways, Stat3 is constitutively activated at high frequency in a wide diversity of cancers and is a promising molecular target for cancer therapy. Thus, repression of p53 expression by Stat3 is likely to have an important role in development of tumors, and targeting Stat3 represents a novel therapeutic approach for p53 reactivation in many cancers lacking p53 mutations.

Original languageEnglish (US)
Pages (from-to)7432-7440
Number of pages9
JournalMolecular and Cellular Biology
Volume25
Issue number17
DOIs
StatePublished - Sep 2005

Fingerprint

Neoplasms
Mutation
p53 Genes
Up-Regulation
Binding Sites
Apoptosis
DNA
Therapeutics
Growth

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cell Biology

Cite this

Niu, G., Wright, K. L., Ma, Y., Wright, G. M., Huang, M., Irby, R., ... Yu, H. (2005). Role of Stat3 in regulating p53 expression and function. Molecular and Cellular Biology, 25(17), 7432-7440. https://doi.org/10.1128/MCB.25.17.7432-7440.2005

Role of Stat3 in regulating p53 expression and function. / Niu, Guilian; Wright, Kenneth L.; Ma, Yihong; Wright, Gabriela M.; Huang, Mei; Irby, Rosalyn; Briggs, Jon; Karras, James; Cress, W. Douglas; Pardoll, Andrew Mark; Jove, Richard; Chen, Jiangdong; Yu, Hua.

In: Molecular and Cellular Biology, Vol. 25, No. 17, 09.2005, p. 7432-7440.

Research output: Contribution to journalArticle

Niu, G, Wright, KL, Ma, Y, Wright, GM, Huang, M, Irby, R, Briggs, J, Karras, J, Cress, WD, Pardoll, AM, Jove, R, Chen, J & Yu, H 2005, 'Role of Stat3 in regulating p53 expression and function', Molecular and Cellular Biology, vol. 25, no. 17, pp. 7432-7440. https://doi.org/10.1128/MCB.25.17.7432-7440.2005
Niu G, Wright KL, Ma Y, Wright GM, Huang M, Irby R et al. Role of Stat3 in regulating p53 expression and function. Molecular and Cellular Biology. 2005 Sep;25(17):7432-7440. https://doi.org/10.1128/MCB.25.17.7432-7440.2005
Niu, Guilian ; Wright, Kenneth L. ; Ma, Yihong ; Wright, Gabriela M. ; Huang, Mei ; Irby, Rosalyn ; Briggs, Jon ; Karras, James ; Cress, W. Douglas ; Pardoll, Andrew Mark ; Jove, Richard ; Chen, Jiangdong ; Yu, Hua. / Role of Stat3 in regulating p53 expression and function. In: Molecular and Cellular Biology. 2005 ; Vol. 25, No. 17. pp. 7432-7440.
@article{01ae7021ad5b43a6b1db025d98764a16,
title = "Role of Stat3 in regulating p53 expression and function",
abstract = "Loss of p53 function by mutation is common in cancer. However, most natural p53 mutations occur at a late stage in tumor development, and many clinically detectable cancers have reduced p53 expression but no p53 mutations. It remains to be fully determined what mechanisms disable p53 during malignant initiation and in cancers without mutations that directly affect p53. We show here that oncogenic signaling pathways inhibit the p53 gene transcription rate through a mechanism involving Stat3, which binds to the p53 promoter in vitro and in vivo. Site-specific mutation of a Stat3 DNA-binding site in the p53 promoter partially abrogates Stat3-induced inhibition. Stat3 activity also influences p53 response genes and affects UV-induced cell growth arrest in normal cells. Furthermore, blocking Stat3 in cancer cells up-regulates expression of p53, leading to p53-mediated tumor cell apoptosis. As a point of convergence for many oncogenic signaling pathways, Stat3 is constitutively activated at high frequency in a wide diversity of cancers and is a promising molecular target for cancer therapy. Thus, repression of p53 expression by Stat3 is likely to have an important role in development of tumors, and targeting Stat3 represents a novel therapeutic approach for p53 reactivation in many cancers lacking p53 mutations.",
author = "Guilian Niu and Wright, {Kenneth L.} and Yihong Ma and Wright, {Gabriela M.} and Mei Huang and Rosalyn Irby and Jon Briggs and James Karras and Cress, {W. Douglas} and Pardoll, {Andrew Mark} and Richard Jove and Jiangdong Chen and Hua Yu",
year = "2005",
month = "9",
doi = "10.1128/MCB.25.17.7432-7440.2005",
language = "English (US)",
volume = "25",
pages = "7432--7440",
journal = "Molecular and Cellular Biology",
issn = "0270-7306",
publisher = "American Society for Microbiology",
number = "17",

}

TY - JOUR

T1 - Role of Stat3 in regulating p53 expression and function

AU - Niu, Guilian

AU - Wright, Kenneth L.

AU - Ma, Yihong

AU - Wright, Gabriela M.

AU - Huang, Mei

AU - Irby, Rosalyn

AU - Briggs, Jon

AU - Karras, James

AU - Cress, W. Douglas

AU - Pardoll, Andrew Mark

AU - Jove, Richard

AU - Chen, Jiangdong

AU - Yu, Hua

PY - 2005/9

Y1 - 2005/9

N2 - Loss of p53 function by mutation is common in cancer. However, most natural p53 mutations occur at a late stage in tumor development, and many clinically detectable cancers have reduced p53 expression but no p53 mutations. It remains to be fully determined what mechanisms disable p53 during malignant initiation and in cancers without mutations that directly affect p53. We show here that oncogenic signaling pathways inhibit the p53 gene transcription rate through a mechanism involving Stat3, which binds to the p53 promoter in vitro and in vivo. Site-specific mutation of a Stat3 DNA-binding site in the p53 promoter partially abrogates Stat3-induced inhibition. Stat3 activity also influences p53 response genes and affects UV-induced cell growth arrest in normal cells. Furthermore, blocking Stat3 in cancer cells up-regulates expression of p53, leading to p53-mediated tumor cell apoptosis. As a point of convergence for many oncogenic signaling pathways, Stat3 is constitutively activated at high frequency in a wide diversity of cancers and is a promising molecular target for cancer therapy. Thus, repression of p53 expression by Stat3 is likely to have an important role in development of tumors, and targeting Stat3 represents a novel therapeutic approach for p53 reactivation in many cancers lacking p53 mutations.

AB - Loss of p53 function by mutation is common in cancer. However, most natural p53 mutations occur at a late stage in tumor development, and many clinically detectable cancers have reduced p53 expression but no p53 mutations. It remains to be fully determined what mechanisms disable p53 during malignant initiation and in cancers without mutations that directly affect p53. We show here that oncogenic signaling pathways inhibit the p53 gene transcription rate through a mechanism involving Stat3, which binds to the p53 promoter in vitro and in vivo. Site-specific mutation of a Stat3 DNA-binding site in the p53 promoter partially abrogates Stat3-induced inhibition. Stat3 activity also influences p53 response genes and affects UV-induced cell growth arrest in normal cells. Furthermore, blocking Stat3 in cancer cells up-regulates expression of p53, leading to p53-mediated tumor cell apoptosis. As a point of convergence for many oncogenic signaling pathways, Stat3 is constitutively activated at high frequency in a wide diversity of cancers and is a promising molecular target for cancer therapy. Thus, repression of p53 expression by Stat3 is likely to have an important role in development of tumors, and targeting Stat3 represents a novel therapeutic approach for p53 reactivation in many cancers lacking p53 mutations.

UR - http://www.scopus.com/inward/record.url?scp=23844503025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844503025&partnerID=8YFLogxK

U2 - 10.1128/MCB.25.17.7432-7440.2005

DO - 10.1128/MCB.25.17.7432-7440.2005

M3 - Article

VL - 25

SP - 7432

EP - 7440

JO - Molecular and Cellular Biology

JF - Molecular and Cellular Biology

SN - 0270-7306

IS - 17

ER -